Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
By Justin S. Smith, A. Perry, T. Borell, Hyun K. Lee, J. O'fallon, Sandra M. Hosek, D. Kimmel, A. Yates, P. Burger, B. Scheithauer and 1 more. Journal of Clinical Oncology, 2000
809 citations recorded by the source corpus.
Subfields: Genetics, Neurology
View Paper: https://www.semanticscholar.org/paper/ed6a3eff7fd1ed7bbb2a929527fe98ffb0e96ecb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. (2006, background): “Anticipating that chromosomal analysis might identify clinically important subsets of patients,(7) paraffin sections and blood were requested from all participants, and during the trial, the potential prognostic and predictive value of 1p and 19q allelic loss in AO was reported.(8,9)”
- Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013, methodology): “The status of chromosomes 1p and 19q was assessed by fluorescence in situ hybridization.(18)”
- The WHO Classification of Tumors of the Nervous System (2002, background): “In addition, 1p loss (or combined 1p and 19q loss) is associated with significantly prolonged patient survival when compared with oligodendrogliomas that lack these alterations (19, 20).”
- A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. (2006, methodology): “Isolated deletions of 19q are relatively common in astrocytic and oligodendroglial tumors (6, 9, 10, 23).”